The FDA’s unapproved drug initiative has had an impact on catheter lock therapy for home infusion patients. Patients who require a central venous access device (CVAD) are at a significant risk for catheter-associated bloodstream infections. The lack of options and high cost have created an urgent need in the U.S. for FDA-approved central line catheter lock solutions.
In this white paper learn about:
- Challenges and costs of Ethanol Lock Therapy (ELT)
- Need for FDA-approved alternative lock solutions
Related healthcare insights
Article
On average, Optum Infusion nurses spend approximately 1,300 hours per year providing care to patients. Hilary, an Optum Infusion nurse, knows this firsthand.
Video
Our infusion care ecosystem is based on a commitment to clinical innovation and providing consistent, convenient and compassionate care.
Article
Optum tackles the many issues infusion pharmacy care faces as it serves vulnerable patients with acute needs and complex conditions.